Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Status:
Completed
Trial end date:
2017-07-17
Target enrollment:
Participant gender:
Summary
This open-label study is being conducted to confirm the safety, pharmacokinetic profile and
efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema
attacks in patients, from 2 up to and including 13 years of age.